risedronic acid risedronic acid risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. it slows down the cells which break down bone. it's used to treat or prevent osteoporosis, and treat paget's disease of bone. it is taken by mouth. risedronic acidclinical datatrade namesactonel, atelvia, benet, othersahfs/drugs.commonographlicense data us dailymed: risedronic pregnancycategory au: b3 routes ofadministrationby mouthatc codem05ba07 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only in general: ℞ (prescription only) pharmacokinetic databioavailability0.63%protein binding~24%metabolismnoneelimination half-life1.5 hexcretionkidney and fecalidentifiers iupac name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid cas number105462-24-6 ypubchem cid5245iuphar/bps3176drugbankdb00884 nchemspider5055 nuniikm2z91756zkeggd00942d03234chemblchembl923 npdb ligandris (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid2023563 echa infocard100.116.436 chemical and physical dataformulac7h11no7p2molar mass283.113 g·mol−13d model (jsmol)interactive image smiles oc(cc1cccnc1)(p(=o)(o)o)p(=o)(o)o inchi inchi=1s/c7h11no7p2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9h,4h2,(h2,10,11,12)(h2,13,14,15) nkey:iidjrnmfwxdhid-uhfffaoysa-n n ny (what is this?) (verify) it was patented in 1984 and approved for medical use in 1998. pharmacology relative potency bisphosphonate relative potency etidronate 1 tiludronate 10 pamidronate 100 alendronate 100-500 ibandronate 500-1000 risedronate 1000 zoledronate 5000 society and culture brand names it is produced and marketed by warner chilcott, sanofi-aventis, and in japan by takeda under the trade names actonel, atelvia, and benet. it is also available in a preparation that includes a calcium carbonate supplement, as actonel with calcium. controversies in january 2006 p&g and its marketing partner sanofi-aventis filed a lanham act false claims lawsuit against rival drugmakers roche and glaxosmithkline claiming false advertising about boniva. the manufacturers of boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. in a ruling on september 7, 2006, u.s. district judge paul a. crotty rejected p&g's attempted injunction. p&g was criticized for attempting to "preserve its market share by denigrating boniva". judge crotty wrote that "roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented". in 2006, p&g faced controversy over its handling of clinical research involving risedronate (news reports and discussion). in common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.